What's Going On With Palisade Bio Stock On Thursday?
What's Going On With Palisade Bio Stock On Thursday?
The Common Warrants will have an exercise price of $1.40 per share, will be exercisable at issuance, and will have a term expiring five years from issuance.On Thursday, Palisade Bio Inc (NASDAQ:PALI) stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from Benzinga Pro.
在星期四，Palisade Bio Inc (纳斯达克:PALI) 的股票交易价格上涨，成交量达到2697万，而根据Benzinga Pro的数据，平均成交量为10.768万。
Palisade Bio priced an underwritten public offering for gross proceeds of approximately $5 million.
Palisade Bio定价了一项承销的公开发行，预计总收益约为500万美元。
The offering comprises 158,000 Class A Units and 3.12 million Class B Units. The price per Class A Unit is $1.525, and the price per Class B Unit is $1.5249.
此次发行包括158,000个A类单位和312万个B类单位。每个A类单位的价格为1.525美元，每个B类单位的价格为1.5249美元。
The Common Warrants will have an exercise price of $1.40 per share, will be exercisable at issuance, and will have a term expiring five years from issuance.
普通Warrants的行使价格为每股1.40美元，发行时即可行使，行使期限在发行后五年到期。
The company will use the net proceeds primarily to fund the Phase 1 trial of PALI-2108, pre-clinical studies, research and development, and working capital.
公司将主要使用净收益资助PALI-2108的第一阶段试验、临床前研究、研发及营运资金。
Last week, Palisade Bio revealed preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human study for PALI-2108 for Ulcerative Colitis.
上周，Palisade Bio公布了其正在进行的针对PALI-2108用于溃疡性结肠炎的第一阶段人体研究的前三个单次递增剂量（SAD）组的初步结果。
Preliminary results appear to indicate that PALI-2108 was safe and well tolerated in the first three cohorts (n=24; 6:2 active to placebo) at 15mg, 50mg, and 150mg, with no treatment-related dose reductions, no Treatment-Related Adverse Events (TRAEs), no Serious Adverse Events (SAEs), and no treatment-related lab abnormalities in any subject.
初步结果似乎表明，PALI-2108在前三个组别（n=24；6:2有效对照）中安全且耐受良好，剂量分别为15mg、50mg和150mg，没有治疗相关的剂量减少，没有治疗相关的不良事件（TRAEs），没有严重不良事件（SAEs），也没有任何受试者出现治疗相关的实验室异常。
Preliminary pharmacokinetics data from the first cohorts demonstrated delayed release of the PDE4 inhibitor active suggesting PALI-2108 is performing as designed with colonic bioactivation.
来自首个组别的初步药代动力学数据表明PDE4抑制剂活性延迟释放，表明PALI-2108在结肠生物活化方面表现符合预期。
Based on the findings with this preliminary safety data, the company is advancing toward its planned crossover study to evaluate the effects of food on pharmacokinetics, followed by multiple ascending dose (MAD) cohorts and, finally, a multiple-dose cohort of patients with Ulcerative Colitis.
根据这些初步安全数据的发现，该公司正在推进其计划中的交叉研究，以评估食物对药物代谢动力学的影响，随后是多次递增剂量（MAD）队列，最后是溃疡性结肠炎患者的多次给药队列。
The company is on track to report topline data from this study in the first half of 2025.
该公司计划在2025年上半年报告本研究的初步数据。
As of September 30, the company had cash and cash equivalents of $8.0 million. The company believes it has sufficient cash to fund its planned operations through the first quarter of 2025.
截至9月30日，该公司持有现金及现金等价物800万美元。公司认为其有足够的现金来资助其计划的运营，直到2025年第一季度。
Price Action: PALI stock is trading 51.5% higher at $2.12 at last check Thursday.
价格动态：PALI股票在上周四的最后检查时交易上涨51.5%，至2.12美元。
- 3D Systems Agrees To Sell Geomagic Portfolio For $123 Million, AI And 3D Printing Take Center Stage
- 3D系统同意以12300万美元的价格出售Geomagic产品组合，人工智能和3D打印成为焦点。
